Shahryar Khoshtinat Nikkhoi

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy

Shahryar Khoshtinat Nikkhoi, Geng Li, Suha Eleya et al. · Frontiers in Immunology · 2023 · 47 citations · Full text

Pharmacy, Immunology, Oncology +17

Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin

Alireza Farasat, Fatemeh Rahbarizadeh, Davoud Ahmadvand et al. · Journal of Liposome Research · 2018 · 34 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting

Shahryar Khoshtinat Nikkhoi, Fatemeh Rahbarizadeh, Saeed Ranjbar et al. · Molecular Immunology · 2018 · 29 citations

Pharmacy, Molecular Pharmaceutics, Oncology +17

Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept

Shahryar Khoshtinat Nikkhoi, Fatemeh Rahbarizadeh, Davoud Ahmadvand et al. · European Journal of Pharmaceutical Sciences · 2018 · 28 citations

Pharmacy, Medicinal Chemistry, Oncology +12

Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice

Shahryar Khoshtinat Nikkhoi, Ge Yang, Hajar Owji et al. · Journal for ImmunoTherapy of Cancer · 2024 · 22 citations · Full text

Life Sciences, Immunology, Oncology +17